APOLLOHOSPNSEApollo Hospitals Enterprise Limited· Healthcare ServicesHighPositive
Announced Tue, 10 Feb, 2026 · 18:03 IST

Apollo Hospitals declares Rs 10 interim dividend, Q3 PAT up 35%

APOLLOHOSP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+4.0%Reaction day
₹7216.00
prior close
₹7405.00
announcement price
After-mkt
timing
Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.2%+3.9% vs market
Hospital peers, median of 23sector+1.3%+2.7% vs sector

On the reaction day the stock moved 3.9 pts more than Nifty 100 and 2.7 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.6
10m
+2.7
15m
+2.7
30m
+2.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+4.0+0.2+3.9+1.3+2.7
Next day
+4.5-0.4+4.9+2.3+2.2
2d
+4.3-1.7+6.0+0.8+3.5
3d
+5.1-0.9+6.0+1.1+4.0
4d
+5.0-0.7+5.7+2.0+3.0
5d
+5.9-0.3+6.2+2.5+3.4
1w
+5.2-1.3+6.4-0.3+5.5
15d
+8.0-4.3+12.3-2.0+10.0
1m
+6.7-7.4+14.2-2.6+9.3
2m
+4.1-7.4+11.4-1.9+6.0
3m
+12.0-6.7+18.6+9.0+3.0
UpDownMarket · Nifty 100Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board declared an interim dividend of Rs 10 per share (200% of face value Rs 5) for FY26. Record date is 16-Feb-2026, payment on or before 27-Feb-2026. Q3FY26 consolidated revenue grew 17% YoY to Rs 6,477 crore, EBITDA up 27% to Rs 965 crore, PAT up 35% to Rs 502 crore. YTD revenue Rs 18,623 crore, PAT Rs 1,412 crore (up 34%). Demerger scheme for pharmacy business into Apollo Healthtech pending NCLT approval.

Likely market impact

Positive: Strong Q3 earnings growth and dividend declaration reward shareholders; demerger scheme for the pharmacy vertical continues to progress.